We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biolasers Light Up Circulating Tumor Cells in Bloodstream of Cancer Patients

By LabMedica International staff writers
Posted on 07 Jan 2025
Print article
Image: Researchers have developed new approach for identifying circulating tumor cells in patients with pancreatic and lung cancer (Photo courtesy of Jacob Dwyer/Michigan Medicine)
Image: Researchers have developed new approach for identifying circulating tumor cells in patients with pancreatic and lung cancer (Photo courtesy of Jacob Dwyer/Michigan Medicine)

As tumors grow, they release cells into the bloodstream, known as circulating tumor cells (CTCs). Although these cells are vastly outnumbered by millions of other blood cells, detecting them early can significantly enhance treatment outcomes. For example, pancreatic cancer is typically diagnosed too late for effective treatment, contributing to its poor prognosis. Similarly, lung cancer detection, especially for recurrence after treatment, is also challenging. Traditional methods for detecting CTCs involve labeling specific proteins on tumor cell surfaces with fluorescent dyes, making the cells easier to spot in blood samples. However, this method has drawbacks. Some CTCs may not express these proteins, causing them to be overlooked. Additionally, these methods miss valuable insights into the internal workings of the cancer cells, and often involve techniques that damage or kill the cells, preventing further analysis.

To find a way to detect CTCs while they remain alive, researchers from the University of Michigan (Ann Arbor, MI, USA) developed a new approach for identifying these cells in patients with pancreatic and lung cancer. The researchers turned to biolaser technology. While this approach still uses dyes to stain cancer cells, it does not kill them, and instead of focusing on proteins found on the cell surface, it targets something common to all cells—their nuclei. For their study, the researchers first passed blood samples from pancreatic cancer patients through a circular maze called Labyrinth, which pre-separates the CTCs, as they are slightly larger than other white blood cells. They then placed the tumor cells between two mirrors and directed an excitation laser at them, one cell at a time. When the excitation was strong enough, the cells emitted a laser, and these cells were referred to as "cell lasers." The laser emission from these cells is significantly stronger than what is observed with traditional fluorescent techniques.

Moreover, the images generated by laser emissions are distinct; while fluorescent images make the cells appear as glowing spheres, laser emissions reveal more complex shapes that provide insights into the organization of DNA inside the cancer cells. However, the differences in the laser emissions are subtle. To overcome this, the researchers used machine learning for enhanced accuracy. With the help of the Deep Cell-Laser Classifier model, they were able to identify pancreatic cancer cells with 99% accuracy. Impressively, the model, initially trained with pancreatic cancer cells, could also detect lung cancer cells without any additional training, as detailed in the study published in Biosensors and Bioelectronics. Moving forward, the researchers aim to develop a device capable of isolating cancer cells after detection. They also plan to use the unique light patterns produced by the cells to gain a deeper understanding of which tumors are more aggressive or resistant to treatment.

“With our system, if you want to collect circulating tumor cells, you have to remove the top mirror, which can cause the cell to move and then you lose track of it,” said Xudong (Sherman) Fan, professor of biomedical engineering. “We want to develop a system where cells move along one-by-one through the laser excitation spot and then go through a cell sorting device that helps us sort and collect cells for subsequent analysis.”

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more